158 related articles for article (PubMed ID: 36791335)
1. Quantitative Characterization of Clinically Relevant Drug-Metabolizing Enzymes and Transporters in Rat Liver and Intestinal Segments for Applications in PBPK Modeling.
Sharma S; Singh DK; Mettu VS; Yue G; Ahire D; Basit A; Heyward S; Prasad B
Mol Pharm; 2023 Mar; 20(3):1737-1749. PubMed ID: 36791335
[TBL] [Abstract][Full Text] [Related]
2. Ontogeny of Small Intestinal Drug Transporters and Metabolizing Enzymes Based on Targeted Quantitative Proteomics.
Kiss M; Mbasu R; Nicolaï J; Barnouin K; Kotian A; Mooij MG; Kist N; Wijnen RMH; Ungell AL; Cutler P; Russel FGM; de Wildt SN
Drug Metab Dispos; 2021 Dec; 49(12):1038-1046. PubMed ID: 34548392
[TBL] [Abstract][Full Text] [Related]
3.
Singh DK; Ahire D; Davydov DR; Prasad B
Drug Metab Dispos; 2024 Apr; ():. PubMed ID: 38641346
[TBL] [Abstract][Full Text] [Related]
4. Utility of Quantitative Proteomics for Enhancing the Predictive Ability of Physiologically Based Pharmacokinetic Models Across Disease States.
Sharma S; Suresh Ahire D; Prasad B
J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S17-S35. PubMed ID: 33205430
[TBL] [Abstract][Full Text] [Related]
5. Age-related changes in mRNA levels of hepatic transporters, cytochrome P450 and UDP-glucuronosyltransferase in female rats.
Kawase A; Ito A; Yamada A; Iwaki M
Eur J Drug Metab Pharmacokinet; 2015 Jun; 40(2):239-44. PubMed ID: 24899460
[TBL] [Abstract][Full Text] [Related]
6. Quantitative prediction of breast cancer resistant protein mediated drug-drug interactions using physiologically-based pharmacokinetic modeling.
Costales C; Lin J; Kimoto E; Yamazaki S; Gosset JR; Rodrigues AD; Lazzaro S; West MA; West M; Varma MVS
CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1018-1031. PubMed ID: 34164937
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Tissue Abundance of Non-Cytochrome P450 Drug-Metabolizing Enzymes by Quantitative Proteomics between Humans and Laboratory Animal Species.
Basit A; Fan PW; Khojasteh SC; Murray BP; Smith BJ; Heyward S; Prasad B
Drug Metab Dispos; 2022 Mar; 50(3):197-203. PubMed ID: 34969659
[TBL] [Abstract][Full Text] [Related]
8. Prediction of Atorvastatin Pharmacokinetics in High-Fat Diet and Low-Dose Streptozotocin-Induced Diabetic Rats Using a Semiphysiologically Based Pharmacokinetic Model Involving Both Enzymes and Transporters.
Wang Z; Yang H; Xu J; Zhao K; Chen Y; Liang L; Li P; Chen N; Geng D; Zhang X; Liu X; Liu L
Drug Metab Dispos; 2019 Oct; 47(10):1066-1079. PubMed ID: 31399507
[TBL] [Abstract][Full Text] [Related]
9. Prandial state and biological sex modulate clinically relevant efflux transporters to different extents in Wistar and Sprague Dawley rats.
Gavins FKH; Dou L; Qin Y; Madla CM; Murdan S; Basit AW; Mai Y; Orlu M
Biomed Pharmacother; 2023 Apr; 160():114329. PubMed ID: 36731343
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms governing different pharmacokinetics of ginsenosides and potential for ginsenoside-perpetrated herb-drug interactions on OATP1B3.
Jiang R; Dong J; Li X; Du F; Jia W; Xu F; Wang F; Yang J; Niu W; Li C
Br J Pharmacol; 2015 Feb; 172(4):1059-73. PubMed ID: 25297453
[TBL] [Abstract][Full Text] [Related]
11. Quantification of Four Efflux Drug Transporters in Liver and Kidney Across Species Using Targeted Quantitative Proteomics by Isotope Dilution NanoLC-MS/MS.
Fallon JK; Smith PC; Xia CQ; Kim MS
Pharm Res; 2016 Sep; 33(9):2280-8. PubMed ID: 27356525
[TBL] [Abstract][Full Text] [Related]
12. A repository of protein abundance data of drug metabolizing enzymes and transporters for applications in physiologically based pharmacokinetic (PBPK) modelling and simulation.
Ladumor MK; Thakur A; Sharma S; Rachapally A; Mishra S; Bobe P; Rao VK; Pammi P; Kangne H; Levi D; Balhara A; Ghandikota S; Joshi A; Nautiyal V; Prasad B; Singh S
Sci Rep; 2019 Jul; 9(1):9709. PubMed ID: 31273226
[TBL] [Abstract][Full Text] [Related]
13. Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions.
Hanke N; Gómez-Mantilla JD; Ishiguro N; Stopfer P; Nock V
Pharm Res; 2021 Oct; 38(10):1645-1661. PubMed ID: 34664206
[TBL] [Abstract][Full Text] [Related]
14. Protein Abundance of Clinically Relevant Drug Transporters in the Human Liver and Intestine: A Comparative Analysis in Paired Tissue Specimens.
Drozdzik M; Busch D; Lapczuk J; Müller J; Ostrowski M; Kurzawski M; Oswald S
Clin Pharmacol Ther; 2019 May; 105(5):1204-1212. PubMed ID: 30447067
[TBL] [Abstract][Full Text] [Related]
15. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.
Bruyère A; Declèves X; Bouzom F; Ball K; Marques C; Treton X; Pocard M; Valleur P; Bouhnik Y; Panis Y; Scherrmann JM; Mouly S
Mol Pharm; 2010 Oct; 7(5):1596-607. PubMed ID: 20604570
[TBL] [Abstract][Full Text] [Related]
16. In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-glycoprotein and Breast Cancer Resistance Protein: Part II. The Impact of Cross-Laboratory Variations of Intestinal Transporter Relative Expression Factors on Predicted Drug Disposition.
Harwood MD; Achour B; Neuhoff S; Russell MR; Carlson G; Warhurst G; Rostami-Hodjegan A
Drug Metab Dispos; 2016 Mar; 44(3):476-80. PubMed ID: 26842595
[TBL] [Abstract][Full Text] [Related]
17. Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters.
Poondru S; Ghicavii V; Khosravan R; Manchandani P; Heo N; Moy S; Wojtkowski T; Patton M; Haas GP
Clin Transl Sci; 2022 May; 15(5):1131-1142. PubMed ID: 35118821
[TBL] [Abstract][Full Text] [Related]
18. Effects of Chrysin and Its Major Conjugated Metabolites Chrysin-7-Sulfate and Chrysin-7-Glucuronide on Cytochrome P450 Enzymes and on OATP, P-gp, BCRP, and MRP2 Transporters.
Mohos V; Fliszár-Nyúl E; Ungvári O; Bakos É; Kuffa K; Bencsik T; Zsidó BZ; Hetényi C; Telbisz Á; Özvegy-Laczka C; Poór M
Drug Metab Dispos; 2020 Oct; 48(10):1064-1073. PubMed ID: 32661014
[TBL] [Abstract][Full Text] [Related]
19. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
[TBL] [Abstract][Full Text] [Related]
20. Robust physiologically based pharmacokinetic model of rifampicin for predicting drug-drug interactions via P-glycoprotein induction and inhibition in the intestine, liver, and kidney.
Asaumi R; Nunoya KI; Yamaura Y; Taskar KS; Sugiyama Y
CPT Pharmacometrics Syst Pharmacol; 2022 Jul; 11(7):919-933. PubMed ID: 35570332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]